Home > Press > Do titanium dioxide particles from orthopedic implants disrupt bone repair?
![]() |
The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience CREDIT Mary Ann Liebert, Inc., publishers |
Abstract:
Researchers from the Mayo Clinic have proposed that negative cellular responses to titanium-based nanoparticles released from metal implants interfere in bone formation and resorption at the site of repair, resulting in implant loosening and joint pain. Their review of recent scientific evidence and call for further research to characterize the biological, physical, and chemical interactions between titanium dioxide nanoparticles and bone-forming cells is published in BioResearch Open Access, a peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on theBioResearch Open Access website.
Jie Yao, Eric Lewallen, PhD, David Lewallen, MD, Andre van Wijnen, PhD, and colleagues from the Mayo Clinic, Rochester, MN and Second Affiliated Hospital of Soochow University, China, coauthored the article entitled "Local Cellular Responses to Titanium Dioxide from Orthopedic Implants The authors examined the results of recently published studies of titanium-based implants, focusing on the direct and indirect effects of titanium dioxide nanoparticles on the viability and behavior of multiple bone-related cell types. They discuss the impact of particle size, aggregation, structure, and the specific extracellular and intracellular (if taken up by the cells) effects of titanium particle exposure.
"The adverse effects of metallic orthopedic particles generated from implants are of significant clinical interest given the large number of procedures carried out each year. This article reviews our current understanding of the clinical issues and highlights areas for future research," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.
Research reported in this publication was supported by the National Institutes of Health under Award Numbers R01 AR049069 and F32 AR068154. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
####
About Mary Ann Liebert, Inc./Genetic Engineering News
About the Journal
BioResearch Open Access is a peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Head of Astellas Global Regenerative Medicine and Chief Scientific Officer, Astellas Institute for Regenerative Medicine (Marlborough, MA), and Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
For more information, please click here
Contacts:
Kathryn Ryan
914-740-2250
Copyright © Mary Ann Liebert, Inc./Genetic Engineering News
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related Links |
Related News Press |
News and information
Controlling chemical catalysts with sculpted light January 15th, 2021
Nanomedicine
Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021
Single-dose COVID-19 vaccine triggers antibody response in mice January 8th, 2021
Nanocrystals that eradicate bacteria biofilm January 8th, 2021
Detecting COVID-19 antibodies in 10-12 seconds January 8th, 2021
Discoveries
Physicists propose a new theory to explain one dimensional quantum liquids formation January 15th, 2021
Announcements
Controlling chemical catalysts with sculpted light January 15th, 2021
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Controlling chemical catalysts with sculpted light January 15th, 2021
Safety-Nanoparticles/Risk management
No nanoparticle risks to humans found in field tests of spray sunscreens December 2nd, 2020
Study: Nanoparticles produced from burning coal result in damage to mice lungs, suggesting toxicity to humans February 5th, 2020
NIOSH requests data to help develop exposure limits for nanomaterials February 1st, 2020
Nanobiotechnology
Chemists invent shape-shifting nanomaterial with biomedical potential It converts from sheets to tubes and back in a controllable fashion January 13th, 2021
Nanoparticle vaccine for COVID-19 January 8th, 2021
Single-dose COVID-19 vaccine triggers antibody response in mice January 8th, 2021
Nanocrystals that eradicate bacteria biofilm January 8th, 2021
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |